Navigation Links
Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
Date:10/28/2008

Study results to be presented at 2008 ICAAC/IDSA Joint Meeting

ROCKVILLE, Md., Oct. 28 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat infectious diseases of epidemic potential, announces the successful demonstration of synergistic activities and improvement of minimal inhibitory concentration (MIC) resulting from in vitro combination studies of Sequella lead TB drug candidate, SQ109, and Tibotec's lead TB drug candidate, TMC207. Both drug candidates are currently undergoing human clinical studies.

Results from these studies were presented on October 28th at the Interscience Conference on Anti-Microbial Agents and Chemotherapeutics (ICAAC) and Infectious Disease Society of America (IDSA) joint meeting in Washington, DC.

The collaboration between Sequella and Tibotec was designed to investigate in vitro interactions of SQ109 for synergistic, additive, or antagonistic activity in the presence of TMC207, using a number of clinical and laboratory strains of both drug sensitive and drug resistant M. tuberculosis (MTB). In vitro interactions investigated included synergy studies, rate of killing, post antibiotic effect and intracellular activity against MTB in macrophages.

There were no antagonistic activities observed in any combination studies. SQ109 and TMC207 in combination were either synergistic or additive with the various MTB strains and showed increased rate of killing, enhanced post antibiotic effect and intracellular killing activity. Results showed that the SQ109 and TMC207 drug combination was extraordinary potent, with greater than 90% kill of MTB as early as 1 day after drug combination exposure.

Dr. Carol Nacy, CEO of Sequella said, "We are very pleased to be collaborating with Tibotec, a world renowned product development organization, and we look forward to our continuing partnership to examine these important drug synergies in animal models
'/>"/>

SOURCE Sequella, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
2. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
3. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
4. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
5. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
6. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
7. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
11. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...all/--OptimerPharmaceuticals,Inc.(Nasdaq: OPTR )is...hCareConferenceatTheNewYorkPalaceinNewYorkCityonDe...tp://www.newscom.com/cgi-bin/prnh/20090413/LA97352...llbeaccessibleontheInvestorspageoftheCompany,swebs...tationwillbeavailableatthesamelocationfor30daysfol...
(Date:11/24/2009)...-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),abiopha...izingnovelpainmanagementtherapies,todayannouncedth...ectiveNovember19,2009.Mr.Orwinisa20-yearsalesandma...beeninstrumentalinthelaunchofseveralimportantthera...President,BioOncologyBusinessUnitatGenentech,Inc.,...
(Date:11/23/2009)...wswire/--FebeDurango-Rueda,52,aColombiannational,p...todefraudtheExport-ImportBankoftheUnitedStates(Ex-...neyGeneraloftheCriminalDivisionLannyA.BreuerandAct...,OfficeoftheInspectorGeneral. ,, Durangopleaded...rtinWashingtontoaone-countcriminalinformationcharg...
Breaking Medicine Technology:NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director 2NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director 3Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2Evolution Evidence Overturned 61598 1Evolution Evidence Overturned 61598 2Evolution Evidence Overturned 61598 3Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment 14893 1Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment 14893 2Hand washing Compliance Computer Auto Log on Log off and Patient Fall detection are Enabled by Real Time Location System 28RTLS 29 with Sub room Lo 14890 1Hand washing Compliance Computer Auto Log on Log off and Patient Fall detection are Enabled by Real Time Location System 28RTLS 29 with Sub room Lo 14890 2Hand washing Compliance Computer Auto Log on Log off and Patient Fall detection are Enabled by Real Time Location System 28RTLS 29 with Sub room Lo 14890 3Hand washing Compliance Computer Auto Log on Log off and Patient Fall detection are Enabled by Real Time Location System 28RTLS 29 with Sub room Lo 14890 4
... 8 AstraZeneca (NYSE: AZN ) and Targacept, Inc.... clinical trial of AZD3480 (TC-1734) conducted by ...nia (CDS), known as the HALO trial. , , AZD34...al significance on the primary endpoints, improvem...ntegNeuro computerized test battery. AZD3480 was g...
...Oncology,Company today reported updated results fr...inical trials of VELCADE based combinations for th...nts with previously untreated,multiple myeloma (MM...bserved,in one study comparing VELCADE and dexamet...ethasone (VAD), as well as in another study compar...
Other Medicine Technology:AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 2AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 4Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 2Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 3Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 4Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 5Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 6Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 7
(Date:11/24/2009)...elease is available in German . , Internati...n with cancer is very good as far as survival is c...of life, pain, and long-term consequences of the d...udies. This is the conclusion of the Institute for...its final report published on 16 October 2009. , ...
(Date:11/24/2009)...bility reduced in those with undesirable blood lev... (HealthDay News) -- Abnormal cholesterol levels c...e, a new study has found. , U.S. researchers an...Heart, Lung, and Blood Institute,s Framingham Hear... had coronary heart disease at the start of the st...
(Date:11/24/2009)... New York personal injury attorney...the number of a personal injury attorney after a h...local Long Island backyard. , ...w York personal injury attorney David Perecman po...ryone should have the number of a personal injury ...
(Date:11/24/2009)... Mercy Health System will be offer...ry hosted by Robert Epstein, MD, board certified o...ter today at www.MercyWebinars.com , ...ealth System will present a live webinar on LASIK ...rough an office or home computer and is free to an...
(Date:11/24/2009)...OMERSET,N.J.,Nov.24/PRNewswire-FirstCall/--TeamSta...eandadministrativestaffingservices,todayannouncedt...ockfromTheNasdaqGlobalMarkettoTheNasdaqCapitalMark...iveattheopeningofbusinessonWednesday,November25,20...derthesymbol"TSTF."TheNasdaqCapitalMarketisacontin...
Breaking Medicine News(10 mins):Health News:In Germany, children with cancer have a high probability of survival 2Health News:In Germany, children with cancer have a high probability of survival 3Health News:Cholesterol Plays Role in Heart Failure Risk 2Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 2Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 3Health News:Free LASIK Surgery Webinar 2Health News:Free LASIK Surgery Webinar 3Health News:Free LASIK Surgery Webinar 4Health News:TeamStaff Announces Transfer to Nasdaq Capital Market 2Health News:TeamStaff Announces Transfer to Nasdaq Capital Market 3
...e you so disappointed?, CHICAGO, April 10 Disapp...., Why?, It has to do with changing expectations... medium with an attitude,that says, "We need a web... months --,of struggling with web site development...
...TON, Mass. (April 10, 2008)Researchers at Harvard ...s Health, and the Massachusetts Department of Publ...r programs that use electronic medical records to ...ord Support for Public Health, or ESP, was describ...
...trists Recognize Efforts to Safeguard Sight, Promo... Expand Access to Care, WASHINGTON, April 9, 2008...ding important leadership on health care,policy is...in West Virginia and the AOA are working to pass l...
...h study found it shaved 10 to 12 years off biologi...News) -- A person who maintains aerobic fitness ma...analysis shows. , Jogging and other types of aerob...gins in middle age, decreasing about 5 ml/ (kg. mi...
...O, April 9 A new report that features four,leadin...xtended roundtable,discussion on key issues relate...n-and ways in which the industry may best address ...g_issues/2008PrivacyRoundtable.pdf ) that will,be ...
...or adults with muscle-thickening disorder may also...April 9 (HealthDay News) -- The same 10 gene mutat...ng of the heart muscle) in adults are also associa...family history of the condition, the researchers n...
Other Medicine News:Health News:So ... You Went and Got a Pretty Web Site. 2Health News:Researchers pilot new electronic system for infectious illness 2Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2Health News:Aerobic Exercise Keeps You Young 2Health News:Privacy Experts' Roundtable Report Will Highlight Privacy & Security Week 2Health News:Gene Mutations for Rare Heart Disease Also Found in Kids 2
ELB3000 Portable Scale
...ital stability control, analog display modes, mult...measure functions, auto print, and GLP/GMP/ISO out...ck. Touch-key calibration with external weights (...rface, WindowsDirect Capable. 120/240V A/C adapter...
A&D HF-200
Thermometer for Round Water Bath
Medicine Products: